Indoco Remedies

Indoco Remedies FCF/Debt

The Free Cash Flow to Debt Ratio of Indoco Remedies (INDOCO.NS) as of Nov 4, 2026 is -10.56 %. In the previous year, Free Cash Flow to Debt Ratio was -33.04 % — a change of -68.03% (higher).

FCF/Debt

-10.56 %

YoY

-68.03%

Last updated:

Free Cash Flow to Debt Ratio of Indoco Remedies is 2026 -10.56 % . Free Cash Flow to Debt Ratio of Indoco Remedies was 2025 -33.04 % . It decreases by -68.03% higher compared to the previous year.

The Indoco Remedies FCF/Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF/Debt
Date
FCF/Debt
Jan 1, 2019
11.82 INR
Jan 1, 2020
23.95 INR
Jan 1, 2021
2.01 INR
Jan 1, 2022
18.90 INR
Jan 1, 2023
-8.54 INR
Jan 1, 2024
-40.47 INR
Jan 1, 2025
-33.04 INR
Jan 1, 2026
-10.56 INR
The Indoco Remedies FCF/Debt history
YEARFCF/DebtYoY
-10.56 %-68.03%
-33.04 %-18.36%
-40.47 %+373.76%
-8.54 %-145.20%
18.90 %+838.17%
2.01 %-91.59%
23.95 %+102.62%
11.82 %-299.54%
-5.92 %-85.29%
-40.27 %-427.51%
12.29 %-47.75%
23.53 %-70.40%
79.50 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Indoco Remedies Stock analysis

What does Indoco Remedies do? Indoco Remedies Ltd. manufactures and markets formulations and active pharmaceutical ingredients, offering medicines across therapeutic categories like diabetology, respiratory, and women's health. Its product portfolio includes brands such as Cyclopam, Sensodent-K, Karvol Plus, and Rexidin M, targeting both domestic and international markets. The company serves healthcare providers and consumers through its extensive range of pharmaceutical products, with subsidiaries supporting its global operations. The firm's revenue streams derive from the sale of finished dosage forms and APIs, with key brands like Cital UTI and Kidodent catering to specific medical needs. International markets represent a significant segment, complementing domestic sales, while subsidiaries such as Indoco Remedies Czech sro and Indoco Remedies UK Limited facilitate regional distribution and market expansion. Products like Lignox A and Homide are positioned for niche therapeutic applications, driving demand among healthcare professionals and patients. Indoco Remedies is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Indoco Remedies stock

Free Cash Flow to Debt Ratio of Indoco Remedies is -10.56 % in 2026.

Free Cash Flow to Debt Ratio of Indoco Remedies changed from -33.04 % to -10.56 %, representing a -68.03% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow to Debt Ratio Indoco Remedies since 2006 – with annual values, charts, and detailed analysis.

FCF/Debt measures the percentage of total debt that could be repaid from free cash flow. It is a stricter measure than OCF/Debt as it accounts for capital expenditures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow to Debt Ratio's Indoco Remedies with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Indoco Remedies

All Key Metrics — Indoco Remedies